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Abstract Reduced uptake of
123I- metaiodobenzylguani-
dine (MIBG) on cardiac gammagraphy and impaired odor
identiﬁcation are markers of neurodegenerative diseases
with Lewy bodies (LB) as a pathological hallmark, such as
idiopathic Parkinson’s disease (IPD). LRRK2 patients
present with a clinical syndrome indistinguishable from
IPD, but LB have not been found in some cases. Patients
with such mutations could behave differently than patients
with IPD with respect to MIBG cardiac uptake and olfac-
tion. We studied 14 LRRK2 patients, 14 IPD patients
matched by age, gender, disease duration and severity, and
13 age and gender matched control subjects. Olfaction was
analyzed through the University of Pennsylvania Smell
Identiﬁcation Test (UPSIT). MIBG cardiac uptake was
evaluated through the H/M ratio. The late H/M was
1.44 ± 0.31 for LRRK2 patients, 1.19 ± 0.15 for PD
patients, and 1.67 ± 0.16 for control subjects. LRRK2
patients presented lower but not statistically signiﬁcant
MIBG cardiac uptake than controls (p = 0.08) and sig-
niﬁcant higher uptake than PD patients (p = 0.04). UPSIT
mean scores were 21.5 ± 7.3 for LRRK2 patients,
18.7 ± 6.2 for IPD patients and 29.7 ± 5.7 for control
subjects. UPSIT score was lower in both LRRK2 and PD
than in controls. In LRRK2 patients a positive correlation
was found between myocardial MIBG uptake and UPSIT
scores, (R = 0.801, p\0.001). In LRRK2 patients, MIBG
cardiac uptake was less impaired than in PD; a positive
correlation between MIBG cardiac uptake and UPSIT
scores was observed. As MIBG cardiac reduced uptake and
impaired odor identiﬁcation are markers of LB pathology,
this ﬁndings may represent neuropathological heterogene-
ity among LRRK2 patients.
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Introduction
The clinical picture of patients with parkinsonism carrying
LRRK2 gene mutations (LRRK2) is indistinguishable from
that of Parkinson’s disease (PD) [1–3]. Postmortem
descriptions of these patients indicate that the pathological
substrate is heterogeneous with Lewy bodies (LB) in some
cases, and with tau-immunopositive neuroﬁbrillary tangle
pathology, nigral degeneration with ubiquitin immunore-
active neuronal inclusions or pure nigral cell loss, in some
others [1–9].
123I-MIBG cardiac scintigraphy (MIBG) reﬂects pre-
synaptic sympathetic system integrity, and reduced myo-
cardial uptake of this tracer suggests cardiac sympathetic
denervation. Pathologic studies have demonstrated the
presence of LB pathology and degeneration of the distal
axons in the sympathetic ganglia and nerves of the cardiac
plexus from patients with PD and dementia with LB [10],
indicating that LB pathology itself might cause cardiac
sympathetic denervation and low MIBG uptake [11]. Since
MIBG cardiac uptake is normal in other parkinsonian
syndromes in which LB are absent [12, 13], reduced uptake
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DOI 10.1007/s00415-010-5896-6of this tracer has been proposed as a marker for those
neurodegenerative disorders related to LB pathology.
Impaired odor detection has been also suggested as a
potential marker for those disorders with an underlying LB
pathology and to differentiate PD from other parkinsonian
syndromes [14–17]. Since the presence of LB in LRRK2 is
inconstant, and both MIBG reduced cardiac uptake and
impaired odor identiﬁcation, are proposed markers for the
presence of LB pathology, patients with such mutations
could behave differently than patients with IPD with
respect to cardiac denervation and olfaction.
This is a prospective study to investigate the MIBG
cardiac uptake and smell function in patients with PD
carrying LRRK2 mutations.
Methods
Design
This was a prospective parallel group to study the MIBG
cardiac uptake and smell function in patients with PD
carrying LRRK2 mutations. The study protocol was
approved by the local ethics committee. All patients signed
an informed consent before entering the study.
Subjects of the study
Fourteen patients with parkinsonism carrying previously
identiﬁed pathogenic mutations of the LRRK2 gene
(LRRK2) were enrolled in the study. Of these patients, 13
presented the LRRK2 G2019S mutation and one, the
R1441G mutation. Only two out of the 14 patients were
relatives (mother and son). LRRK2 mutations were identi-
ﬁed as previously described [3, 8]. We also included 14 PD
patients diagnosed according to accepted clinical criteria
[18] that were matched in age, gender, disease duration, and
severity to patients with LRRK2 mutations. All PD patients
were studied for the possible existence of the LRRK2
G2019S and codon 1441 mutations which were ruled out in
all of them. We also included 13 age and gender matched
control subjects without any neurological disorder that were
selected among spouses of the PD and LRRK2 patients.
Exclusion criteria for entering the study were the same
for all three groups of subjects and were mainly determined
by those circumstances that could potentially modify
MIBG cardiac uptake or smell function: (a) previous his-
tory of diabetes mellitus, peripheral neuropathy, cardiopa-
thy or coronariopathy; (b) patients receiving any
medication known to modify the MIBG uptake such as
tricyclic antidepressants, MAO inhibitors, calcium antag-
onists, neuroleptics and sympathomimetics and adrenergic
drugs [19] (dopaminergic drugs were not discontinued
since they are not among the drugs known to interfere with
MIBG uptake); (c) proven iodine allergy; (d) patients with
previous (such as signiﬁcant cranial traumatism) or current
(such as having a cold or tobacco consumption) conditions
or rhinologic disorders known to impair the sense of smell
[20]; (e) dementia or signiﬁcant cognitive impairment
(Mini-Mental State Examination score \25) that could
impair (or interfere with) odor identiﬁcation.
Clinical assessment
After collection of detailed aspects of their clinical history,
all IPD and LRRK2 patients were assessed through the
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS),
Schwab & England scale and Hoehn & Yahr staging sys-
tem at the ﬁrst visit when entering the study after the usual
morning dose of antiparkinsonian medication. Antiparkin-
sonian and other pharmacological treatments were recor-
ded and levodopa equivalent daily dose was calculated.
Olfaction testing
Olfaction was evaluated through the University of Penn-
sylvania Smell Identiﬁcation Test (UPSIT), commercially
known as the Smell Identiﬁcation Test
TM
(Sensonics,
Spanish version) during the same day when MIBG cardiac
scintigraphy was performed. The UPSIT is a rapid and
easy-to-administer method to quantitatively assess human
olfactory function, and includes 40 odors that should be
identiﬁed. Scores range from 0 to 40 and higher scores
entail a better olfactory recognition or function.
MIBG cardiac gammagraphy
Following thyroid gland blocking with potassium iodide
(300 mg), anterior planar images of the chest were
obtained and data were collected for 30 min, and 4 h after
injection of 111 MBq of MIBG a static image was obtained
with a 128 9 128 matrix using a double-head gamma
camera system (Siemens E-CAM Dual-head, Erlangen,
Germany). The organ uptake of MIBG was determined by
setting the regions of interest (ROI), which were manually
drawn around the left cardiac ventricle, and the upper
mediastinum. The average counts per pixel in the heart and
mediastinum were determined within each region of
interest to calculate the heart-to-mediastinum (H/M) ratio
at 30 min (early ratio) and 4 h (late ratio).
Statistical analyses
Since many variables were not normally distributed, as
pointed out by the Kolmogorov–Smirnov test, non-para-
metric tests were used to assess differences between
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Whitney U test were used to compare the means of groups
for multiple comparisons and in pairs, respectively. To
determine whether there was a relationship among MIBG
ratios and UPSIT score or other variables such as age,
gender, disease duration, and Hoehn & Yahr stage in any
group of subjects, Spearman correlation coefﬁcient was
obtained. A signiﬁcance level of \0.05 was used. The
statistical analyses were performed using commercially
available software (SPSS, Version 17.0).
Results
The main demographic and clinical data of the subjects
included in this study are summarized in Table 1. The
results of the early and late H/M ratios obtained through the
cardiac MIBG gammagraphy study are shown in the
Table 2. The mean early H/M ratio in LRRK2 patients was
signiﬁcantly higher than in PD (p = 0.02) and slightly
lower than in controls (p = 0.06). The mean early H/M
ratio in the PD group was signiﬁcantly lower than in
controls (p\0.01).
The mean late H/M ratio in LRRK2 patients was not
signiﬁcantly lower than in controls (p = 0.08), but was
signiﬁcantly different than in PD patients (p = 0.04). The
late H/M ratio in PD patients was signiﬁcantly lower than
in controls (p\0.01). There was not any signiﬁcant
overlap between late H/M ratios values in PD patients and
those found in control subjects. By contrast, the late H/M
ratios of LRRK2 patients presented a greater dispersion of
values, which were intermediate between PD and control
subjects (Fig. 1).
The mean UPSIT scores are also shown in Table 1.
LRRK2 patients presented slightly greater scores than PD
patients, but this difference was not statistically signiﬁcant
(p = 0.31), and both LRRK2 patients and PD showed
signiﬁcantly lower scores than controls (p\0.01 and
p\0.01, respectively).
In LRRK2 patients a positive correlation was found
between both MIBG early or late H/M ratios and the
UPSIT score (for early H/M ratio: R = 0.72, p = 0.004;
and for delayed H/M ratio: R = 0.71, p = 0.006). These
correlations are shown in Fig. 2. Both PD patients and
control subjects did not show any correlation between
early or late H/M ratios and UPSIT scores (in PD patients,
for early H/M ratio: R = 0.49, p = 0.08; and for delayed
H/M ratio: R = 0.32, p = 0.26; in controls, for early H/M
ratio: R = 0.29, p = 0.34; and for delayed H/M ratio:
R =- 0.11, p = 0.71). Most of the LRRK2 patients
showing altered MIBG ratio where those presenting
abnormal UPSIT scores, while all LRRK2 patients with
normal MIBG ratio also had normal UPSIT scores
(Fig. 3). There were no statistical differences in any
demographic or clinical data in LRKK2 patients with
normal MIBG uptake compared with those presenting
reduced MIBG uptake (Table 3).
We did not ﬁnd any correlation between either early or
late H/M ratios and other clinical variables such as age,
gender, disease duration, and Hoehn & Yahr stage in any
group of subjects, but a non signiﬁcant trend was
observed between disease duration and H/M ratios in
Table 1 Demographic and clinical data of the subjects of the study
IPD LRRK2 Controls p
(n = 14) (n = 14) (n = 13)
Sex (male/female) 8/6 8/6 7/6
Age (years), mean ± SD (range) 62.1 ± 11.6 (45–85) 61.9 ± 12.6 (43–92) 63.5 ± 11.9
(45–85)
0.89
a
Smokers 1 3 2
Age at PD diagnosis (years), mean ± SD (range) 52.1 ± 12.6 (36–81) 52.1 ± 14.3 (33–86) – 0.95
b
Duration from PD diagnosis (years), mean ± SD
(range)
9.9 ± 4.2 (4–18) 9.8 ± 5.9 (4–28) – 0.54
b
UPDRS part II (On) score, mean ± SD (range) 6.6 ± 4.4 (0–14) 11.1 ± 8.6 (1–26) – 0.35
b
UPDRS part III (On) score, mean ± SD (range) 15.6 ± 9.1 (2–38) 20.3 ± 13.5 (8–48) – 0.51
b
UPDRS part IV score, mean ± SD (range) 3.6 ± 3.5 (0–10) 3.7 ± 3.3 (0–10) – 0.87
b
Schwab & England (On) Scale, mean ± SD (range) 90.0 ± 7.8 (70–100) 87.9 ± 11.2 (70–100) – 0.80
b
Hoehn & Yahr (On) stage, mean ± SD (range) 1.7 ± 0.7 (1–3) 1.9 ± 0.7 (1–3) – 0.60
b
Levodopa equivalent daily dose (milligrams),
mean ± SD (range)
1,145.1 ± 441.4
(300–1,735)
921.0 ± 350.2
(285–1,434)
– 0.15
b
a Kruskal–Wallis analysis
b Mann–Whitney U test
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123Table 2 Early and late myocardial
123I-MIBG H/M ratios and UPSIT scores obtained in LRRK2, IPD patients, and healthy matched control
subjects
LRRK2 IPD Controls p
Early H/M ratio 1.49 ± 0.24 (1.09–1.82) 1.31 ± 0.14 (1.13–1.64) 1.66 ± 0.13 (1.39–1.87) 0.02*
0.06
§
\0.001
?
Late H/M ratio 1.44 ± 0.31 (0.96–1.94) 1.19 ± 0.15 (1.04–1.59) 1.67 ± 0.16 (1.30–1.90) 0.04*
0.08
§
\0.001
?
UPSIT score 21.5 ± 7.3 (8–31) 18.7 ± 6.2 (9–32) 29.7 ± 5.7 (19–38) 0.31*
0.007
§
\0.001
?
Numbers are the mean and standard deviation. The range appear in brackets
* Mann–Whitney U test: p value for LRRK2 versus IPD comparison
§ Mann–Whitney U test: p value for LRRK2 versus control subjects comparison
? Mann–Whitney U test: p value for IPD versus control subjects comparison
Fig. 1 Scatter plot showing early (a) and late (b) H/M ratios for
123I-MIBG cardiac uptake in patients with idiopathic Parkinson’s
disease (IPD), patients with parkinsonism and LRRK2 mutations
(LRRK2-PD) and controls. Circles represent individual values; the
bar refers to the mean H/M ratio in each group
Fig. 2 Relationship between early (a) and delayed (b) H/M ratio for
123I-MIBG cardiac uptake and UPSIT scores in patients with parkinsonism
and LRRK2 mutations. (Early: R = 0.62 p\0.02; late: R = 0.68 p = 0.01)
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r =- 0.56; p = 0.04).
Discussion
The cardiac uptake of MIBG was signiﬁcantly less
impaired in LRRK2 than in PD patients. In LRRK2
patients, abnormalities in smell function correlated with
MIBG cardiac uptake impairment.
These ﬁndings are in agreement with a previous study
showing normal MIBG myocardial uptake in three out of
six patients carrying the LRRK2 G2019S mutation [21],
and in most patients with I2020T or G2019S [22]. In
the present study, olfactory function was not signiﬁcantly
different in LRRK2 patients and PD patients, a similar
ﬁnding that was previously shown in another study in
parkinsonian patients carriers of the G2019S mutation in
which UPSIT scores were lower than that in healthy
controls and similar to that found in patients with PD
[23].
Similar studies have been conducted in patients with
parkin mutations [22, 24, 25]. In most of these patients the
cardiac uptake of MIBG was found to be normal. Post-
mortem studies of some of these patients revealed the
preservation of cardiac sympathetic nerves [24]. In addi-
tion, olfactory function in patients carrying parkin muta-
tions has been shown to be similar to healthy controls and
better than those observed in PD cases [26]. The most
frequent neuropathological substrate in patients with par-
kinsonism related to parkin mutations is nigral degenera-
tion without distinctive pathological inclusions [27, 28].
The differences in myocardial MIBG uptake and olfactory
function between parkin and PD patients is probably
reﬂecting the preservation of cardiac sympathetic plexus
and olfactory anatomical structures in parkin patients, and
lend support to the notion that both hyposmia and abnormal
myocardial MIBG scintigraphy are indicators of LB
pathology.
In this context, the cardiac gammagraphy ﬁndings of the
present study may reﬂect that the presence of LB in
LRRK2 patients is inconstant, variable, or that LB are
present in fewer amounts. To date, the neuropathology
associated with the LRRK2 G2019S mutation has been
described in 21 cases with a clinical picture of progressive
parkinsonism [2, 4–9, 21, 29]. In 18 of these cases, typical
LB pathology was present, non-speciﬁc nigral degeneration
similar to that described in patients with parkin gene
Fig. 3 UPSIT scores of patients with normal and abnormal delayed
MIBG ratios
Table 3 Summary of the demographic data, disease features and UPSIT score in LRRK2 patients with normal MIBG uptake compared to
LRRK2 patients with reduced MIBG uptake (cut-off for abnormal delayed H/M ratio = 1.43)
LRRK2 patients with
normal delayed H/M
ratio (n = 5)
LRRK2 patients with
reduced delayed H/M
ratio (n = 9)
p
Sex (female, %) 3 (60%) 3 (33.3%) 0.58
Age (years), mean ± SD (range) 67.4 ± 17.6 (43–92) 58.9 ± 8.3 (49–70) 0.44
Age at PD diagnosis (years), mean ± SD (range) 60.2 ± 19.6 (33–86) 47.7 ± 8.9 (35–64) 0.19
Duration from PD diagnosis (years), mean ± SD (range) 7.2 ± 2.7 (4–10) 11.2 ± 6.9 (6–28) 0.15
UPDRS part II (ON) score, mean ± SD (range) 12.6 ± 11.0 (3–26) 10.33 ± 7.6 (1–23) 0.8
UPDRS part III (ON) score, mean ± SD (range) 20.8 ± 16.7 (9–48) 20.0 ± 12.4 (8–42) 1.0
UPDRS part IV score, mean ± SD (range) 2.6 ± 3.8 (0–9) 4.3 ± 3.0 (0–10) 0.24
Schwab & England (On) Scale, mean ± SD (range) 90.0 ± 12.2 (70–100) 86.7 ± 11.2 (70–100) 0.61
Hoehn & Yahr (On) stage, mean ± SD (range) 1.8 ± 0.4 (1–2) 1.9 ± 0.8 (1–3) 0.9
Levodopa equivalent daily dose (LED) (milligrams),
mean ± SD (range)
642.0 ± 341.2 (285–1,010) 1,076.0 ± 255.7 (705–1,434) 0.29
UPSIT Score, mean ± SD (range) 28.4 ± 2.6 (25–31) 17.8 ± 6.1 (8–25) \0.01*
* Statistically signiﬁcant: p\0.05
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roﬁbrillary tangle pathology in one case. Thus, the most
frequent histological ﬁndings encountered in parkinsonism
with LRRK2 G2019S mutation is LB pathology, although
up to 14% of the cases can present another pathological
substrate without the presence of LB and Lewy neurites.
The neuropathological ﬁndings associated with LRRK2
R1441G mutations are nigral cell loss without distinctive
pathological inclusions, described so far in a single case
[9]. In the single patient of the present series carrying the
R1441G mutation, a severe hyposmia and marked low
MIBG uptake was found suggesting the presence of
underlying LB pathology in this case.
A strong positive correlation between UPSIT scores and
MIBG uptake was found in LRRK2 patients. This fact
enhances the idea of a close association between cardiac
uptake of MIBG and olfactory function. Reduced uptake of
MIBG and reduced smell sense are usually decreased in PD
patients, even in patients with a recent diagnosis of the
disease, suggesting an early involvement by the patholog-
ical process associated to LB of both, the cardiac sympa-
thetic nerve and olfactory bulb [30–34]. Some studies have
found that MIBG uptake correlate with olfactory function
in PD patients [35], a correlation that is not found in
multiple system atrophy [36]. In addition, a recent studied
have shown that smell loss is associated with baroreﬂex
failure and cardiac noradrenergic denervation in PD
patients [37]. All these observations may indicate that
cardiac sympathetic nervous system degenerates in parallel
with the olfactory system. In our study, smell function was
not signiﬁcantly different in LRRK2 than in PD patients,
although it was slightly better and there was a statistical
trend. This fact probably reﬂects that smell function can be
inﬂuenced by many independent factors while MIBG car-
diac uptake is more speciﬁc of the presence of LB
pathology.
In our study, the disease duration and severity was not
correlated with either the MIBG uptake parameters or with
UPSIT scores. LRRK2 patients with abnormal MIBG scans
had younger age of onset, longer disease duration and
higher L-dopa doses than the LRRK2 patients with normal
MIBG scans, but none of these differences reached statis-
tical signiﬁcance. In our opinion, the differences in disease
duration and age at onset could hardly explain differences
in MIBG. LRRK2 patients with normal MIBG also had
normal UPSIT score (in the range of controls), in contrast
to those with abnormal MIBG who had abnormal UPSIT
scores (in the range of IPD), suggesting that normal MIBG
likely reﬂect absence of LB pathology. The possible
association of MIBG uptake with the severity and duration
of the disease is controversial. Different studies have
shown that the disease severity is not correlated [38] or can
be correlated [39, 40] with MIBG myocardial uptake. It has
been suggested that degeneration of the cardiac sympa-
thetic nerves and the olfactory bulb nerve occurs early in
the disease process, even before the onset of degeneration
at the nigral level [11]. This fact may account for the
decreased cardiac uptake of MIBG and smell loss at the
beginning of the disease and could explain the lack of
correlation of MIBG myocardial uptake and the clinical
markers of disease progression.
In conclusion, MIBG cardiac uptake in parkinsonian
patients with LRRK2 mutations is abnormal but less
impaired than in IPD, a ﬁnding that might be attributed to
neuropathological heterogeneity among LRRK2 patients.
MIBG reduced uptake is correlated with worse olfactory
function in LRRK2 PD patients, supporting the notion that
both abnormalities can be speciﬁc markers for the presence
of LB in patients with LRRK2 mutations. It would be of
great interest to follow-up these patients and make serial
MIBG in order to observe the possible changes taking
place after disease progression. The hypothesis stated in
this study can be conﬁrmed only through post-mortem
analyses of the LRRK2 brains. Most of LRRK2 patients
enrolled in the study accepted brain donation.
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